Abstract
To the Editor.— The use of levodopa (L-DOPA; dihydroxyphenylalanine) for the treatment of Parkinson's disease has been satisfactorily demonstrated in many cases when other therapeutic measures fail to act. It has been reported in the available literature 1,2 that the administration of levodopa might cause psychiatric symptoms (eg, hallucinations, ideas of reference, or irritability) as untoward side effects. Our own experience indicates that levodopa aggravates the mental status of patients with chronic schizophrenia with drug-induced parkinsonism. 3 We have also found that levodopa increased the severity of depression in two patients with Parkinson's disease and caused auditory and visual hallucinations in one patient without previous mental illness. A decrease or gradual withdrawal of levodopa resulted in the disappearance of psychiatric symptoms in all three patients. These findings could be in agreement with those biochemical theories of schizophrenia where biogenic amines metabolism seems to play a preponderant role. 4 As this
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
